ELD607 ORAI1 antagonist increases bacterial clearance from the lung

Ended Project Grant Awarded Last action

Award ID
R42AI155107
Recipient
Awarding agency
Obligated
$5,275,996

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Originally
Funding
  • $4,276,156.00 Federal
  • $999,840.00 Non-federal
Place of performance
North Carolina, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $988,238 $0
Amendment ELD607 ORAI1 antagonist increases bacterial clearance from the lung - hospital acquired pneumonia (HAP) is most common cause of mortality in intensive care… $988,238 $0
Amendment -$42,804 $0
Amendment $42,804 $0
Amendment $42,804 $42,804
Amendment -$42,804 -$42,804
Amendment $0 $0
Amendment $0 $0
Amendment $999,840 $0
Amendment $999,840 $999,840
Amendment $0 $0
Amendment $0 $0
Original award $300,000 $0
Show all 15

Quick answers

Who received award R42AI155107?

R42AI155107 was awarded to Eldec Pharmaceuticals, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 22, 2020.

How much is award R42AI155107 worth?

$5,275,996 has been obligated on R42AI155107: $4,276,156 in federal funding and $999,840 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award